Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokineticsSHELTON, Mark J; FORD, Susan L; BORLAND, Julie et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 42, Num 1, pp 61-67, issn 1525-4135, 7 p.Article

Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patientsMARCELIN, Anne-Geneviève; AFFOLABI, Dissou; COSTAGLIOLA, Dominique et al.Journal of medical virology. 2004, Vol 74, Num 1, pp 16-20, issn 0146-6615, 5 p.Article

The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavirCORBETT, Amanda H; ERON, Joseph J; FISCUS, Susan A et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 36, Num 4, pp 921-928, issn 1525-4135, 8 p.Article

Effect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epitheliumISROR, Mohd; MITCHELL, Danielle; ALAM, Samina et al.Antiviral therapy (London). 2010, Vol 15, Num 2, pp 253-265, issn 1359-6535, 13 p.Article

Long-term results of initial therapy with abacavir and lamivudine combined with efavirenz, amprenavir/ritonavir, or stavudineBARTLETT, John A; JOHNSON, Judy; HERRERA, Gisela et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 3, pp 284-292, issn 1525-4135, 9 p.Article

Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juiceDEMARLES, D; GILLOTIN, C; BONAVENTURE-PACI, S et al.Antimicrobial agents and chemotherapy. 2002, Vol 46, Num 5, pp 1589-1590, issn 0066-4804Article

Safety profile and tolerability of amprenavir in patients enrolled in an early access programSCOTT, Trevor; GARRIS, Cindy; ROGERS, Michael et al.Clinical therapeutics. 2001, Vol 23, Num 2, pp 252-259, issn 0149-2918Article

Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir : comparison with ketoconazoleVON MOLTKE, L. L; DUROL, A. L. B; DUAN, S. X et al.European journal of clinical pharmacology. 2000, Vol 56, Num 3, pp 259-261, issn 0031-6970Article

Same patient, new stone composition : amprenavir urinary stoneFEICKE, Antje; RENTSCH, Katharina M; OERTLE, Daniel et al.Antiviral therapy (London). 2008, Vol 13, Num 5, pp 733-734, issn 1359-6535, 2 p.Article

Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected childrenWINTERGERST, U; ENGELHORN, C; KUROWSKI, M et al.AIDS (London). 2000, Vol 14, Num 12, pp 1866-1868, issn 0269-9370Article

Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaksOKUSANYA, Olanrewaju; FORREST, Alan; DIFRANCESCO, Robin et al.Antimicrobial agents and chemotherapy. 2007, Vol 51, Num 5, pp 1822-1826, issn 0066-4804, 5 p.Article

Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrierTHUY THANH TRAN; MITTAL, Aditya; GALES, Tracy et al.Journal of pharmaceutical sciences. 2004, Vol 93, Num 8, pp 2108-2123, issn 0022-3549, 16 p.Article

Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in ratsGAO, Weihua; KAGEYAMA, Michiharu; TAKADA, Kanji et al.Biological & pharmaceutical bulletin. 2003, Vol 26, Num 2, pp 199-204, issn 0918-6158, 6 p.Article

Different evidence of key amprenavir resistance mutations on the efficacy of darunavirDI BIAGIO, Antonio; ROSSO, Raffaella; BRUZZON, Bianca et al.AIDS (London). 2008, Vol 22, Num 3, pp 437-438, issn 0269-9370, 2 p.Article

Response to; Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patientsPICCHIO, Gaston; DE MEYER, Sandra; DE BETHUNE, Marie-Pierre et al.AIDS (London). 2008, Vol 22, Num 1, pp 165-167, issn 0269-9370, 3 p.Article

Détermination simultanée de la concentration plasmatique de l'amprénavir et de l'indinavir par chromatographie liquide haute performance = Simultaneous quantitative determination of amprenavir and indinavir in human plasma by reversed-phase high-performance liquid chromatographyLAUSSINE, S; ROUX, A; DELHOTAL-LANDES, B et al.Annales de biologie clinique (Paris). 2001, Vol 59, Num 2, pp 169-175, issn 0003-3898Conference Paper

Amprénavir : Cinquième inhibiteur de la protéase du HIV, sans progrès démontré = Amprenavir: The fifth HIV protease inhibitor, without proved progressLa Revue Prescrire. 2001, Vol 21, Num 214, pp 101-103, issn 0247-7750, 106 [4 p.]Article

Pharmacokinetics of Concurrent Administration of Fosamprenavir and Atazanavir without Ritonavir in Human Immunodeficiency Virus-Negative SubjectsMCRAE, Marypeace; CLAY, Patrick G; ANDERSON, Peter L et al.Pharmacotherapy. 2009, Vol 29, Num 8, pp 937-942, issn 0277-0008, 6 p.Article

Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patientsTORTI, Carlo; QUIROS-ROLDAN, Eugenia; CAROSI, Giampiero et al.Journal of medical virology. 2004, Vol 74, Num 1, pp 29-33, issn 0146-6615, 5 p.Article

Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure : 1-year resultsRAGUIN, Gilles; POIZAT, Gwendoline; MORAND-JOUBERT, Laurence et al.AIDS (London). 2007, Vol 21, Num 2, pp 241-243, issn 0269-9370, 3 p.Article

Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteersFALCOZ, Christine; JENKINS, Julian M; BYE, Carole et al.Journal of clinical pharmacology. 2002, Vol 42, Num 8, pp 887-898, issn 0091-2700Article

Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patientsDELAUGERRE, Constance; MATHEZ, Dominique; PEYTAVIN, Gilles et al.AIDS (London). 2007, Vol 21, Num 9, pp 1210-1213, issn 0269-9370, 4 p.Article

Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virusKOHLI-PAMNANI, Anita; HUYNH, Phu; LOBO, Francis et al.Annals of allergy, asthma, & immunology. 2006, Vol 96, Num 4, pp 620-623, issn 1081-1206, 4 p.Article

Amprenavir or fosamprenavir plus ritonavir in HIV infection : Pharmacology, efficacy and tolerability profileARVIEUX, Cédric; TRIBUT, Olivier.Drugs (Basel). 2005, Vol 65, Num 5, pp 633-659, issn 0012-6667, 27 p.Article

Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patientsHASSON, Hamid; GIANOTTI, Nicola; DANISE, Anna et al.AIDS (London). 2004, Vol 18, Num 1, pp 123-127, issn 0269-9370, 5 p.Article